Search the Newsreel

Crombie REIT Announces August 2026 Monthly Distribution

New Glasgow, Nova Scotia--(Newsfile Corp. - August 14, 2026) - Crombie Real Estate Investment Trust (TSX: CRR.UN) ("Crombie") today announced a distribution of $0.07583 per Unit for the period from August 1, 2026, to and including August 31, 2026. The distribution will be payable …

Crombie Real Estate Investment Trust (TSX:CRR.UN) Expands Acquisitions, Is The Valuation Premium Still Justified?

Grupo Aeromexico's Chief Commercial Officer Disposes of 355,600 Common Shares via ADSs

Grupo Aeromexico's Chief Commercial Officer, Aaron James Murray, sold 355,600 common shares through American Depositary Shares (ADSs) on August 12, 2026, at a weighted average price of $1.583 per underlying common share. Following this transaction, Murray retains 1,262,530 direct common shares. The sale was …

Promis Neurosciences (NASDAQ:PMN) Stock Price Expected to Rise, Guggenheim Analyst Says

Guggenheim raised its price target for Promis Neurosciences (NASDAQ:PMN) from $69 to $100, maintaining a "Buy" rating, while other analysts have varied ratings but a consensus "Moderate Buy" with a $39.25 target. The clinical-stage biopharmaceutical company's shares opened at $14.93, with a market capitalization …

ProMIS Neurosciences Inc. Stock 12‑Month Price Target Raised to $43.64, Implies 195% Upside

ProMIS Neurosciences Inc. (PMN) has seen its 12-month average price target raised by analysts from $39.21 to $43.64, with forecasts ranging from $18 to $100 per share. This new target suggests a potential upside of approximately 195% based on the August 13 closing price. …

Chardan Capital Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Raises Target Price to $33

Chardan Capital has reiterated its Buy rating for ProMIS Neurosciences (PMN.US) and increased its price target to $33. This positive outlook suggests continued confidence in the company's prospects.

Royal Bank of Canada Grows Stock Holdings in Abercrombie & Fitch Company $ANF

Gem Aromatics Q1FY27 revenue up 9% to ₹830 crore; EBITDA falls 43%

Crompton Greaves Q1FY27 profit rises 15% to ₹143 Cr on ECD strength

ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlights: Zero ARIA-E Cases and Promising Biomarker Signals in Phase 1b Trial

ProMIS Neurosciences (PMN) reported strong Q2 2026 earnings call highlights, emphasizing zero ARIA-E cases and promising biomarker signals in its Phase 1b PRECISE-AD trial. The company maintains a strong cash position of $53.4 million, funding operations through 2027, and is advancing its pipeline candidates …

ASX Waiver Clears Path for Andromeda Metals’ Accelerated Share Purchase Plan

Abercrombie & Fitch (ANF) Stock Sinks As Market Gains: Here's Why

In the latest close session, Abercrombie & Fitch (ANF) was down 3.04% at $108.82. The stock's change was less than the S&P 500's daily gain of 0.65%. Meanwhile, the Dow gained 0.13%, and the Nasdaq, a tech-heavy index, added 0.81%. Prior to today's trading, …

Promis Neurosciences (NASDAQ:PMN) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Promis Neurosciences (NASDAQ:PMN) reported its quarterly earnings, beating analyst estimates by $0.10 with a loss of $1.28 per share. The company highlighted encouraging interim safety results for its Alzheimer's candidate PMN310, with promising biomarker data suggesting target engagement. Promis Neurosciences expects its current cash …

Earnings call transcript: ProMIS Neurosciences posts strong cash position in Q2 2026

ProMIS Neurosciences reported a strong cash position of CAD 53.4 million at the end of Q2 2026, sufficient to fund operations through 2027 and a crucial data readout in Q1 2027. The clinical-stage biotech company shared positive interim safety and biomarker data from its …

ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript

ProMIS Neurosciences (PMN) extends cash runway with $70.1M PIPE amid higher R&D

ProMIS Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences announced its Q2 2026 financial results, ending the quarter with $53.4 million in cash, expected to fund operations through 2027. The company also provided positive blinded six-month interim safety and biomarker results from its PRECISE-AD Phase 1b trial for PMN310 in early …

ProMIS Neurosciences Inc. Q2 2026: Net loss $(11.73)M, Diluted EPS $(1.28) — 10-Q Summary

ProMIS Neurosciences Inc. reported a net loss of $(11.73)M for Q2 2026, with a diluted loss per share of $(1.28), an increase in net loss compared to Q2 2025 but an improvement in diluted EPS. The company generated no product revenue. Key highlights include …

WFCF Q2 Earnings Fall Y/Y as Digital Asset Loss Offsets Margin Gains

Shares of Where Food Comes From Inc. WFCF have declined 4.6% since reporting results for the second quarter of 2026 compared with a 0.3% fall in the S&P 500 over the same period. Over the past month, the stock has decreased 4%, underperforming the …

AQR Capital discloses 5.47% Abercrombie & Fitch (ANF) position in amended 13G

AQR Capital Management, LLC and its parent, AQR Capital Management Holdings, LLC, have filed an amended Schedule 13G disclosing a 5.47% beneficial ownership in Abercrombie & Fitch Co. (ANF) Class A Common Stock. As of June 30, 2026, the AQR entities beneficially own 2,428,332 …

Abercrombie Q2 Preview: Expecting Continued Sales Growth, Shares Fairly Valued (NYSE:ANF)

VISA Chrome Q1 Results FY27: Revenue Rs 120 crore, Net Loss Rs 9 Crore on Consolidated Basis

Bank of America Corp DE Purchases 53,161 Shares of Abercrombie & Fitch Company $ANF

Abercrombie & Fitch Company (NYSE:ANF) Given Average Rating of "Moderate Buy" by Brokerages

Promisia Sets AGM to Seek Shareholder Approval for $25m Chatswood Acquisition

Promisia Wins NZX Waivers for $25m Chatswood Aged Care Acquisition

VISA Chrome Q1 net loss widens to ₹9.56 crore as revenue falls 29%

Goldman Sachs eleva el precio objetivo de Abercrombie ante la proximidad de sus resultados

UBS raises Abercrombie & Fitch stock price target on Q2 beat expectations

Brokers Suggest Investing in Abercrombie (ANF): Read This Before Placing a Bet

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Let's …

VISA Chrome Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Abercrombie & Fitch COO Lipesky sells $1.15m in stock

Scott D. Lipesky, COO of Abercrombie & Fitch Co. (NASDAQ:ANF), sold 10,000 shares for $1.15 million on August 10, 2026, as part of a pre-arranged trading plan. Following the sale, Lipesky directly holds 152,534 shares. This transaction comes amidst recent analyst rating changes and …